Penny Stock Under Rs 10 to Launch Patented Molecular Diagnostic Products in India

Avio Smart Market Stack Limited (ASMS), formerly known as Bartronics India Limited and Huwel Lifesciences, based in Hyderabad, have formally signed a Shareholders’ Agreement. This agreement aimed to jointly scale advanced diagnostic technologies and bring them to institutional and healthcare markets across the country.

Following this, ASMS on March 06, 2026, has initiated an expanded collaboration with Huwel Lifesciences to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India.

India: A Major Market for Infectious Disease Diagnostics

One of the biggest markets for infectious disease diagnostics worldwide is India. Tens of millions of diagnostic tests for infectious diseases like hepatitis, HIV, tuberculosis, and others are performed each year by institutional healthcare networks and national health programs. In India, the diagnostics market for these illnesses alone is estimated to be worth more than Rs 5,000 crore a year.

Huwel Lifesciences’

Huwel Lifesciences has developed multiple patented diagnostic technologies. Several more patents and platforms are presently being developed. Also, the company is building a strong pipeline of new products. The company offers disease detection panels, point-of-care molecular testing equipment, and RT-PCR diagnostic kits.

Huwel's own facilities are used for research, assay development, and manufacturing. As one of the few molecular diagnostics firms in India capable of designing, developing, and producing the majority of the components of its diagnostic platforms in-house, Huwel positions itself as a fully indigenous diagnostics innovator in line with the Government of India's "Make in India" initiative.

Using open RT-PCR systems, Huwel's molecular diagnostic solutions enable quick and affordable tuberculosis detection. Tests can be conducted on RT-PCR laboratory infrastructure, which was extensively used throughout the nation during the COVID-19 pandemic. Scalable public health testing is made possible by this method without necessitating large new infrastructure investments.

The required regulatory approvals and validations have already been obtained for the company's molecular diagnostic platform for tuberculosis. Building on the same technology platform, Huwel has also developed molecular diagnostics for HIV, HPV-based cervical cancer screening, antimicrobial resistance (AMR) surveillance, hepatitis, and several other infectious diseases, using scalable open RT-PCR systems suitable for large-scale testing.

ASMS’ Role in Commercialisation and Market Reach

Under this collaboration, Avio Smart Market Stack will spearhead the go-to-market strategy, institutional engagement, and commercialisation of these technologies. It will leverage its institutional relationships, digital infrastructure capabilities, and extensive experience in executing large-scale programmes to ensure the widespread adoption of Huwel’s innovative diagnostic solutions.

Disclaimer: The article is for informational purposes only and not investment advice.